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Study Objectives. To test the hypothesis that gastric pH would be elevated
above pH 3.0 for at least 2 hours after administration of chewable,
dispersible, buffered didanosine tablets.  Doses tested were 200 mg (two
100-mg tablets) and 400 mg (two 200-mg tablets).  We also sought to
compare these doses with regard to maximum gastric pH (pHmax), time to
pHmax (TpH-max), time that gastric pH exceeds 3.0 (TpH>3), and area under
the gastric pH versus time curve for pH greater than 3.0 (AUCT>pH 3).
Design. Prospective, parallel-group, dose-comparison, gastric pH study.
Setting. General Clinical Research Center, University of Michigan Hospitals,
Ann Arbor, Michigan.
Patients. Nineteen patients infected with human immunodeficiency virus,
aged 30–62 years, and receiving long-term didanosine therapy.
Intervention.  Patients underwent continuous gastric pH monitoring, using
the Heidelberg capsule radiotelemetric pH monitoring device.  After
documentation of a fasting baseline gastric pH below 3.0, patients were
given 180 ml of water (control phase), and gastric pH was allowed to
return to baseline.  After administration of a single, oral dose of didanosine
200 mg or 400 mg with 180 ml of water, gastric pH was recorded until pH
remained below 3.0 for 10 minutes.
Measurements and Main Results.  A mean pHmax of 8.6 (range 6.3–9.5) was
achieved with a TpH-max of 4.1 minutes (range 1–12.0 min).  Mean TpH>3
was 24.9 minutes (range 15–55 min), with an AUCT>pH 3 of 2.6 pH•min-1
(range 1.2–6.9 pH•min-1).  The two doses of didanosine tested did not
differ significantly in mean gastric pH parameters.
Conclusions. After administration of chewable, dispersible, buffered
didanosine tablets, 200 or 400 mg, the mean duration of elevated gastric
pH (TpH>3) was less than 30 minutes, with a range of 15–55 minutes.
Characterization of the magnitude and duration of elevated gastric pH may
allow for earlier administration of other pH-sensitive drugs.  The short
duration of elevated gastric pH may help explain the wide variability in
didanosine bioavailability observed clinically.
Key Words: didanosine, ddI, buffered didanosine tablets, gastric pH, HIV.
(Pharmacotherapy 2004;24(11):1539–1545)
Didanosine is a nucleoside analogue reverse
transcriptase inhibitor recommended as a
component of combination antiretroviral therapy
for patients infected with the human immuno-
PHARMACOTHERAPY  Volume 24, Number 11, 2004
deficiency virus (HIV).  When administered with
other antiretroviral agents, the drug has beneficial
effects on key prognostic values and improves
clinical outcomes.1
Didanosine is susceptible to acid hydrolysis
when administered orally; an estimated 10% of
didanosine is degraded every 2 minutes at pH 3.0
or below.2 Another limitation of didanosine is its
poor solubility at low pH values (pka = 9.1).  As a
result, one oral dosage formulation contains
buffers to prevent degradation of drug in the
gastrointestinal tract and improve its solubility.
One commercially available formulation of
didanosine is a chewable, dispersible tablet
containing calcium carbonate and magnesium
hydroxide buffers.  In order to supply adequate
buffering capacity, each dose of didanosine
requires administration of two tablets.
Didanosine is usually dosed either as 200 mg
(two 100-mg tablets) twice/day or 400 mg (two
200-mg tablets) once/day.  In general, didanosine
is rapidly absorbed after oral administration, with
maximum plasma concentrations occurring in
0.25–1.5 hours.  The oral bioavailability of
chewable, dispersible, buffered didanosine tablets
is 42 ± 12%; however, wide interpatient
variability is observed, possibly resulting from
variations in gastric degradation, gastrointestinal
motility, and transit time.1, 3
The manufacturer of the drug recommends the
twice-daily dosing regimen because more
evidence supports the effectiveness of this dosing
frequency compared with the once-daily regimen.
However, an enteric-coated (without buffers)
formulation of didanosine that is administered
once/day recently has been marketed in the
United States and Europe.  This formulation, as
well as once-daily dosing of the chewable,
dispersible, buffered tablets, should be
considered only for patients whose clinical
management requires once-daily dosing (due to
drug interactions, compliance, etc.).  Only
limited data support the long-term durability of
response with a once-daily dosing regimen of
didanosine.4 Yet, in day-to-day clinical practice,
most patients receive the enteric-coated formu-
lation due to its improved tolerance, the
convenience of once-daily administration, and
the ability to avoid many pH- and cation-based
drug-drug interactions.  The results of this study,
however, may help dispel many of the assump-
tions regarding administration of concomitant
drugs in the presence of gastric pH changes after
ingestion of chewable, dispersible, buffered
didanosine tablets.  In addition, whereas the
enteric-coated formulation is approved for
clinical use in the United States and Europe, the
chewable, dispersible, buffered tablet formulation
is used in less developed countries.
The gastric neutralizing effect of chewable,
dispersible, buffered didanosine tablets has the
potential to interfere with absorption of drugs
that require low gastric pH for dissolution and
absorption.  To our knowledge, no published studies
have characterized the magnitude or duration of
change in gastric pH resulting from the buffering
activity of chewable, dispersible, buffered didano-
sine tablets.  As a result, drug interactions are a
frequent concern when managing complex drug
regimens containing didanosine, and simultaneous
administration of didanosine with food or drugs
that are affected by the buffering effect of didanosine
is not recommended.
The objective of our study was to characterize
the magnitude and duration of elevated gastric
pH in adult patients with HIV infection who
received chewable, dispersible, buffered didanosine
tablets.  We hypothesized that baseline gastric pH
would be increased above pH 3.0 for a minimum
of 2 hours after administration of a single oral
dose of didanosine 200 mg (two 100-mg tablets)
or 400 mg (two 200-mg tablets).  Since the
amount of buffer contained in the chewable,
dispersible, buffered tablets is the same regardless
of tablet strength, we did not anticipate any
differences in magnitude or duration of pH
change between the two doses.
Methods
Patient Selection
Nineteen patients with HIV infection were
recruited from HIV clinic populations at the
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University of Michigan Health System and the
Veterans Affairs Ann Arbor Healthcare System.
Patients were 14 Caucasian and five African-
American men, aged 30–62 years (mean age 44
yrs), who were receiving chewable, dispersible,
buffered didanosine tablets as a component of
their antiretroviral therapy.  We excluded patients
who had a history of dysphagia or swallowing
disorders, or a history of gastrointestinal pathology
that could interfere with gastric pH (e.g., chronic
diarrhea, recent gastrointestinal surgery, pancre-
atitis).  We also excluded those patients taking
drugs that affect gastric pH or gastric emptying
(histamine2-receptor antagonists, proton pump
inhibitors, or metoclopramide).
Study Agent
Didanosine (Videx; Bristol-Myers Squibb,
Princeton, NJ) was purchased from the hospital
pharmacy of the University of Michigan as
chewable, dispersible, buffered tablets for oral
administration in strengths of 100 mg and 200
mg.  Tablets were buffered with calcium carbonate
and magnesium hydroxide.  A single lot of
didanosine was used for the entire study.
Study Design and Procedure
The study protocol was approved by institutional
review boards at the Veterans Affairs Ann Arbor
Healthcare System and the University of Michigan
Health System, as well as the General Clinical
Research Center (GCRC) at the University of
Michigan Hospitals.  All studies were performed
at the GCRC.  Written informed consent was
obtained from the patients before their enroll-
ment in the study.
Patients were instructed to fast for at least 8
hours before arriving in the morning at the
GCRC, as well as for the duration of the study
period.  All prescription and nonprescription
drugs, herbal and nutritional supplements, and
beverages that could alter gastric pH or gastric
motility (e.g., citrus juices, caffeinated and
carbonated beverages) were withheld starting the
night before the morning of the study and for the
duration of gastric pH monitoring.  Subjects
received oral didanosine doses of either 200 mg
(two 100-mg tablets) or 400 mg (two 200-mg
tablets).  Subjects were instructed to thoroughly
chew and swallow two tablets, then rinse their
mouth with 180 ml of water, and swallow.  If
subjects preferred, they could disperse the two
tablets in 120 ml of water and swallow, rinsing
with the remaining 60 ml of water.
The Heidelberg capsule pH monitoring system
(Heidelberg International, Inc., Blairsville, GA)
was employed for continuous gastric pH monitoring.
The Heidelberg capsule is a small, consumable,
nondigestible, radiotelemetric unit that measures
hydrogen ion concentrations in the gastrointestinal
tract.  The Heidelberg capsule was activated by
immersion in a solution of 0.9% sodium chloride
and calibrated with standard pH solutions at pH
1.0 and pH 7.0 at 35°C.  Once activated, the device
transmits a continuous radio signal to an antenna
located in a belt worn by the subject.  The output
of the device is a graph of pH versus time.
The Heidelberg capsule was administered with
180 ml of water, and baseline gastric pH was
obtained for each patient.  The Heidelberg capsule
was maintained in the stomach at approximately
50 cm by tethering the capsule with silk surgical
thread and taping the tethered thread to the
patient’s cheek.  The position of the capsule in
the stomach was indicated by a combination of
tether length (measured for each patient) and
continuous monitoring of gastric pH (approximately
pH ≤ 3.0).  Capsule placement was verified by
abdominal radiograph in patients who had an
elevated gastric pH (pH > 3.0) at baseline.  After
verifying capsule placement, patients whose
baseline pH exceeded 3.0 were excluded from
further participation.
Once baseline pH was established and was
stable for 10 minutes, the patient consumed 180
ml of water, which served as a control phase, as
ingestion of water can elevate gastric pH.  Gastric
pH was monitored continuously until it returned
to baseline and was stable for 10 minutes.  Once
the control phase was completed, the patient
received two tablets of didanosine either 100 mg
(for a total dose of 200 mg) or 200 mg (for a total
dose of 400 mg).  Each patient’s gastric pH was
continuously monitored until it returned to
baseline (or was reduced to < 3.0) and remained
stable for 10 minutes.  The capsule was recovered
at the end of the study and recalibrated to ensure
accuracy.
If the investigator suspected that the capsule
had entered the small intestine, which often is
marked by tugging on the tether along with a
rapid, unreversed elevation of pH, the tether was
pulled back in an attempt to return the capsule to
the stomach.  In the event that pulling back on
the tether failed to relocate the capsule, an
abdominal radiograph was performed to verify
the position of the capsule.
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Data Analysis
A plot of gastric pH versus time was made for
each patient.  Maximum gastric pH (pHmax) and
time to maximum pH (TpH>3) were estimated by
visual inspection of the data.  Area under the pH-
time curve from time zero (administration of
didanosine) to the time of the last pH greater
than 3.0 (AUCT>pH 3) was calculated using the
linear trapezoidal rule.  We determined minimum,
mean, and maximum time in which pH exceeded
3.0 for each patient.
Statistical Analysis
A nonpaired t test comparing the results of the
two dosing groups (200 mg vs 400 mg) was
performed using Statview 5.0.1 (SAS Institute
Inc., Cary, NC).  A p value of 0.05 or less was
considered statistically significant.  Our goal was
to measure a difference in pH of 2 units with a
standard error of 0.5 or confidence interval of ± 1.
Earlier studies of gastric pH in patients with HIV
infection showed a standard deviation of
approximately 1.5.5–7 Based on this information,
we determined that a sample size of nine patients
in each group was needed to yield an 80% chance
of detecting a pH difference of 2 units.  In
addition, a regression model was performed
using SAS for Windows, version 8.02 (SAS
Institute Inc.) to detect any differences in gastric
pH parameters when controlling for baseline
gastric pH.
Results
Eighteen of 19 enrolled patients completed the
study, yielding nine evaluable patients in each
group.  One (5.3%) of the 19 patients was
excluded after demonstrating an elevated fasting
baseline gastric pH (> 3) that was consistent with
decreased acid secretion, as has been reported in
patients with HIV and acquired immunodeficiency
syndrome.8–12 In this patient, the position of the
Heidelberg capsule in the stomach was verified
by abdominal radiograph, and pH calibration of
the capsule was validated before and after place-
ment.  All 19 patients tolerated the Heidelberg
capsule without complaints, and no clinically
significant adverse events were noted during the
conduct of the study.  At the end of each subject’s
study period the Heidelberg capsule was retrieved
and recalibrated with 100% accuracy.
Table 1 summarizes overall gastric pH
parameters for the 18 patients and for the two
dosing groups separately.  Gastric pH versus time
profiles for all 18 patients during baseline
monitoring and after administration of 200-mg or
400-mg oral doses of chewable, dispersible,
buffered didanosine tablets are presented in
Figure 1.  Mean baseline gastric pH values were
statistically different between the 200-mg and
400-mg groups:  1.8 and 2.2, respectively
(p=0.04).  Because a statistical difference in
baseline gastric pH was noted, a statistical
regression model was used to determine if any
differences existed in pH parameters when
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Table 1.  Gastric pH Parameters After Oral Administration of Didanosine
Didanosine Dose
200 mg 400 mg Overall
Measurement (n=9) (n=9) p Value (N=18)
Baseline gastric pH
Mean 1.8 2.2 0.04 2.0
Range 1.2–2.4 1.6–2.6 1.2–2.6
pHmax
Mean 8.7 8.6 0.80 8.6
Range 7–9.5 6.3–9.5 6.3–9.5
TpH-max (min)
Mean 4.2 4.0 0.88 4.1
Range 2.0–10.0 1.0–12.0 1.0–12.0
TpH>3 (min)
Mean 22.7 27.2 0.37 24.9
Range 15.0–36.0 15.0–55.0 15.0–55.0
AUCT>pH 3 (pH•min-1)
Mean 2.4 2.8 0.53 2.6
Range 1.2–4.0 1.5–6.9 1.2–6.9
pHmax = maximum pH; TpH-max = time to maximum pH; TpH>3 = time zero (administration of didanosine)
to the time of the last pH > 3.0; AUCT>pH 3 = area under the pH-time curve for pH > 3.0.
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controlling for baseline gastric pH.  No such
differences were detected (p>0.05).  
After ingestion of 180 ml of water during the
control phase, the magnitude of pH change was
minimal and was similar in each group:  0.7 for
both dose groups.  The 200-mg and 400-mg
groups showed similar results for pHmax (8.7 and
8.6), TpH-max (4.2 min and 4.0 min), and
AUCT>pH 3 (2.4 pH•min-1 and 2.8 pH•min-1),
respectively.  Mean values for the time that
gastric pH exceeds 3.0 (TpH>3) were similar
between the 200-mg and 400-mg groups (22.7
and 27.2 min, respectively) and demonstrated a
wide range of variability, from 15–55 minutes.
Discussion
The advent of highly active antiretroviral
therapy (HAART) has significantly reduced the
morbidity and mortality associated with HIV
infection.  However, HAART regimens are often
complex to manage in terms of the number of
drugs, drug interactions, and adverse effects.
Often, patients receiving HAART are taking drugs
for comorbid conditions, as well as drugs for
prophylaxis and treatment of opportunistic
infections.  Consequently, drug scheduling and
adherence are likely to be problematic for
clinicians and patients.  Coadministration of
chewable, dispersible, buffered didanosine tablets
with certain other drugs has the potential to
result in clinically significant drug-drug
interactions due to chelation interactions or
alterations of gastric pH.  For example, the
calcium and magnesium cations contained in the
buffer formulation of didanosine result in major
chelation interactions with several types of drugs,
including quinolone antibiotics.13, 14 Currently,
the manufacturer recommends that didanosine
be administered at least 2 hours after or 6 hours
before a quinolone antibiotic, due to decreased
quinolone plasma concentrations during
concomitant administration with didanosine.
These buffers are also responsible for drug
interactions due to elevations in gastric pH, as
can occur when didanosine is administered orally
with indinavir,15 itraconazole,16 ketoconazole,17
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Figure 1.  Baseline gastric pH values in 18 patients infected with human immunodeficiency virus and their respective pH values
after administration of oral didanosine 200 mg or 400 mg in the form of chewable, dispersible, buffered tablets.  Data are
presented in box-whisker plots; horizontal lines within each box display the 25th, 50th, and 75th percentiles, and vertical lines
display the 10th and 90th percentiles of gastric pH at each time point.
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delavirdine,8 and atevirdine.18 In addition,
didanosine must be ingested on an empty
stomach, as its bioavailability is decreased by
approximately 50% when taken with food.1, 19, 20
The primary objective of our study was to
characterize the magnitude and duration of
elevated gastric pH in adult patients with HIV
infection after administration of chewable,
dispersible, buffered didanosine tablets.  We
chose pH 3.0 as our critical value because
average gastric pH in humans ranges from
1.0–3.0, and at pH below 3.0, didanosine
degrades approximately 10% every 2 minutes.2
In addition, many drugs are optimally absorbed
at low pH values and are insoluble or degraded at
pH values greater than 3.0.  For example,
delavirdine solubility in vitro decreases
approximately 200-fold when pH increases from
2.0 to 7.5, possibly accounting for the decrease in
the delavirdine area under the concentration-time
curve observed in vivo when concomitantly
administered with antacids.8
Caution should be employed in extrapolating
data from our study to other buffered formu-
lations of didanosine or to children.  Different
didanosine formulations contain different buffers
than the formulation used in our study.  Our
study was conducted with chewable, dispersible,
buffered tablets for oral administration in
strengths of 100 mg or 200 mg.  These tablets are
buffered with calcium carbonate and magnesium
hydroxide.  Each dose must be taken as two
tablets (two 100-mg tablets or two 200-mg
tablets) to provide an adequate amount of buffer.
The buffered powder for the didanosine oral
solution contains a citrate-phosphate buffer
composed of dibasic sodium phosphate, sodium
citrate, and citric acid.
The pediatric powder for didanosine oral
solution is mixed with Extra Strength Mylanta
Liquid (Johnson & Johnson-Merck Consumer
Pharmaceuticals Co., Fort Washington, PA) or
Extra Strength Maalox Plus Suspension (Novartis
Consumer Health, Inc., Parsippany, NJ), both of
which contain aluminum hydroxide and
magnesium hydroxide buffers.  Children under
the age of 18 years were excluded from our study.
The pharmacokinetics of didanosine in pediatric
patients have been found to differ from those in
adults, perhaps due to differences in pediatric
gastrointestinal physiology or to the buffers used
in the pediatric formulation of didanosine.21
Future studies designed specifically to assess the
pediatric formulation of didanosine would be
necessary to assess alterations in gastric pH in
children.
Characterization of the magnitude and
duration of elevated pH may allow for earlier
administration of other pH-sensitive agents.  Our
study characterized the short duration but highly
variable magnitude of change in gastric pH
observed after administration of chewable,
dispersible, buffered tablets.  These data support
the findings of a previous study, which suggested
that administration of indinavir, a pH-sensitive
antiretroviral agent, could be recommended
within 1 hour after ingestion of chewable,
dispersible, buffered didanosine tablets, due to
the short duration of elevated gastric pH after
administration of didanosine.22 However, as
previously reported, it is important to note that
drug interactions due to chelation with
polyvalent (e.g., magnesium, calcium) cations in
the buffer are likely to persist longer than the
effect on gastric pH.13, 14
The short duration of elevated pH after
administration of chewable, dispersible, buffered
didanosine tablets may partly explain the wide
variability in bioavailability observed clinically.  A
single dose of ranitidine 150 mg steadily increases
gastric pH, reaching a pH of approximately 5.0
within 2 hours of administration.2 When
ranitidine is administered orally 2 hours before
didanosine, the bioavailability of didanosine is
increased by 14%.2 Other causes of the wide
range of oral bioavailability may be differences in
gastrointestinal motility and transit time between
patients.1 In our study, one patient demonstrated
a gastric pH greater than 3.0 for 55 minutes,
perhaps due to altered gastrointestinal transit.
Conclusion
We hypothesized that gastric pH would be
elevated (pH > 3.0) for at least 2 hours after
administration of chewable, dispersible, buffered
didanosine 200 mg (two 100-mg tablets) or 400
mg (two 200-mg tablets).  We also anticipated
that gastric pH parameters would not differ
between the two doses.  Our results showed that
the mean duration of elevated gastric pH (TpH>3)
was shorter than hypothesized, with a wide range
of variability.  Our initial hypothesis was based
on didanosine’s rapid absorption after oral
administration, with maximum plasma
concentrations occurring within 0.25–1.5 hours.
The wide variability and short duration of gastric
TpH>3 demonstrated in our study may help
explain the variability in didanosine bioavailability
observed clinically.
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